 |
市場調查報告書
商品編碼
2051409
骨癌藥物市場：按藥物類型、疾病適應症、通路和地區分類Bone Cancer Drugs Market, By Drug Type, By Disease Indication, By Distribution Channel, and By Region |
||||||
價格
簡介目錄
據估計，2026年骨癌藥物市值為15.02億美元，預計到2033年將達到21.678億美元。預計從2026年到2033年，其複合年成長率將達到5.4%。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2025 | 2026年市場規模： | 15.2億美元 |
| 歷史數據時期： | 2020年至2024年 | 預測期： | 2026年至2033年 |
| 2026年至2033年預測期間的複合年成長率： | 5.40% | 2033年市場規模預測： | 21.678億美元 |
癌症是最常見且最致命的慢性疾病之一，由於其高度侵襲性和漫長的病程，死亡率極高。骨癌是一種骨組織不受控制地生長的癌症。骨癌市場根據骨癌的類型進行細分，例如原發性骨癌和轉移性骨癌。原發性骨癌是一種由骨骼及相關組織快速且不受控制地生長引起的癌症。而轉移性骨癌則是指從身體其他部位擴散到骨骼的癌症。骨癌也可進一步細分為骨癌、伊文氏肉瘤、軟骨肉瘤、脊索瘤、纖維肉瘤和骨軟骨瘤。
市場動態
預計在預測期內，骨癌新藥的上市和監管核准的增加將推動市場成長。例如，2021年5月，百時美施貴寶和bluebird bio宣布，其接受多重抗藥性復發或難治性多發性骨髓瘤患者的idekabutagene viclucel（ide-cel；bb2121）生技藥品核准申請（BLA）被美國食品藥物管理局（FDA）駁回。此外，2016年4月，Advacis公司獲得了美國FDA授予的ADXS-HER2簡審類。 ADXS-HER2是一種採用Lm技術的免疫療法產品，針對HER2表達陽性的癌症，用於治療可手術切除的骨癌。美國FDA的快速通道資格將使我們能夠加快研發進程，為患者提供更快、更好的治療。
本次調查的主要特點
- 本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
- 此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略的重要見解。
- 本研究根據以下參數介紹了全球骨癌藥物市場主要公司的概況：公司亮點、產品系列、關鍵亮點、財務表現和策略。
- 透過利用本報告中的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
- 這份全球骨癌藥物市場報告的目標受群眾外包括行業內的各種相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
- 透過分析全球骨癌藥物市場時所使用的各種策略矩陣，相關人員將能夠更輕鬆地做出決策。
目錄
第1章：研究目標與前提條件
- 分析目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
第3章：市場動態、監管與趨勢分析
- 市場動態
- 促進因素
- 抑制因子
- 機會
- 市場趨勢
- 監管趨勢
- 新產品上市及核准
- 併購和合作趨勢
- PEST分析
- 波特的分析
第4章 全球骨癌藥物市場：依藥物類型分類，2021-2033年
- 抗代謝物
- 細胞週期蛋白藥物
- 抗生素
- 其他（例如，RANK配體抑制劑）
第5章 全球骨癌藥物市場：依疾病適應症分類，2021-2033年
- 多發性骨髓瘤
- 骨癌
- 軟骨肉瘤
- 伊文氏肉瘤
第6章 全球骨癌藥物市場：依通路分類，2021-2033年
- 醫院藥房
- 零售藥房
- 網路藥房
第7章 全球骨癌藥物市場：依地區分類，2021-2033年
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
- 中東
- GCC
- 以色列
- 其他中東國家
- 非洲
- 北非
- 中非
- 南非
第8章 競爭情勢
- 公司簡介
- Advaxis, Inc.
- Cellectar Biosciences, Inc.
- OPKO Health, Inc.
- Pfizer Inc.
- Amgen Inc.
- Novartis AG
- Eli Lilly and Company
- Debiopharm Group
- Merck & Co.
- Bayer AG
- Bristol-Myers Squibb Company
- Takeda Pharmaceutical
- Hoffmann-La Roche Ltd.
- Teva Pharmaceutical
第9章
- 參考
- 調查方法
簡介目錄
Product Code: CMI93
Bone Cancer Drugs Market is estimated to be valued at USD 1,500.2 Mn in 2026 and is expected to reach USD 2,167.8 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.4% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1,500.2 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.40% | 2033 Value Projection: | USD 2,167.8 Mn |
Cancer is one of the most prevalent fatal chronic disorders with a high mortality rate due to its extremely invasive nature and prolonged duration of disease. Bone cancer is a type of cancer in which the bone tissues grows in an uncontrollable manner. The market of bone cancer is segmented on the basis of types of bone cancer, such as, primary bone cancer and secondary bone cancer. Primary bone cancer is the type of cancer that originates from rapid and uncontrollable growth of the bone and related tissues. Whereas, Secondary bone cancer is when a cancer that started somewhere else in the body has spread to the bones. The bone cancer is also classified as, osteosarcoma, ewing's sarcoma, chondrosarcoma, chordomas, fibrosarcoma, and admantinomas.
Market Dynamics
The increasing launches of new drugs and regulatory approvals for bone cancer are expected to drive the market growth during the forecast period. For instance, in May 2021, Bristol Myers Squibb and bluebird bio announced that the companies received a Refusal to File letter from the US Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for idecabtagene vicleucel (ide-cel; bb2121) for patients with heavily pre-treated relapsed and refractory multiple myeloma, which was submitted in March 2021. Furthermore, in April 2016, Advaxis, Inc. received the Fast Tract designation from the US FDA for ADXS-HER2, an Lm Technology immunotherapy product which target HER2 expressing cancers for the treatment of surgically-resectable osteosarcoma. The US FDA's Fast Tract designation enables the company to accelerate the development process further assisting the patients with rapid and better treatment.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global bone cancer drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Advaxis, Inc., Cellectar Biosciences, Inc., OPKO Health, Inc., Pfizer Inc., Amgen Inc., Novartis AG, Eli Lilly and Company, Debiopharm Group, Merck & Co, Bayer AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical, F. Hoffmann-La Roche Ltd, and Teva Pharmaceutical.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global bone cancer drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bone cancer drug market.
Market Segmentation
- By Drug Type Insights (Revenue, USD Mn, 2021 - 2033)
- Antimetabolites
- Anthracyclines
- Antibiotics
- Others (RANK ligand inhibitors, etc.)
- By Disease Indication Insights (Revenue, USD Mn, 2021 - 2033)
- Multiple Myeloma
- Osteosarcoma
- Chondrosarcoma
- Ewing's Sarcoma
- By Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Advaxis, Inc.
- Cellectar Biosciences, Inc.
- OPKO Health, Inc.
- Pfizer Inc.
- Amgen Inc.
- Novartis AG
- Eli Lilly and Company
- Debiopharm Group
- Merck & Co.
- Bayer AG
- Bristol-Myers Squibb Company
- Takeda Pharmaceutical
- F. Hoffmann-La Roche Ltd.
- Teva Pharmaceutical
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Disease Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Market Trends
- Regulatory Scenario
- New Product Launches/Approvals
- Merger, Acquisition and Collaboration Scenario
- PEST Analysis
- PORTER's Analysis
4. Global Bone Cancer Drugs Market, By Drug Type, 2021- 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Antimetabolites
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Anthracyclines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Others (RANK ligand inhibitors, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021- 2033, (USD Mn)
5. Global Bone Cancer Drugs Market, By Disease Indication, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Multiple Myeloma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021- 2033, (USD Mn)
- Osteosarcoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021- 2033, (USD Mn)
- Chondrosarcoma
- Introduction
- Ewing's Sarcoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
6. Global Bone Cancer Drugs Market, By Distribution Channel, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021- 2033, (USD Mn)
7. Global Bone Cancer Drugs Market, By Region, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
- Segment Trends
- North America
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 -2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (USD Mn)
- U.S.
- Canada
- Europe
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 -2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (USD Mn)
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 -2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (USD Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 -2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 -2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 -2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2021-2033, (USD Mn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Company Profiles
- Advaxis, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Cellectar Biosciences, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- OPKO Health, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Amgen Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Novartis AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Eli Lilly and Company
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Debiopharm Group
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Merck & Co.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Bayer AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Bristol-Myers Squibb Company
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Takeda Pharmaceutical
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Hoffmann-La Roche Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Teva Pharmaceutical
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Analyst Views
- Advaxis, Inc.
9. Section
- References
- Research Methodology
- About us and Sales Contact
